Abualbishr Alshreef

10PUBLICATIONS
38CO-AUTHORS
Epidemiological modellingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Vision scienceOphthalmology and optometry not elsewhere classifiedSpeech pathology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Nov 26, 2025
Approaches to modeling treatment sequencing in practice: a thematic review of prior NICE appraisals.

Abualbishr Alshreef, Fern Woodhouse, Molly Haycock

|Jun 05, 2025
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma.

Alexey V Danilov, Swetha Kambhampati Thiruvengadam, Kim Linton

|Nov 09, 2024
Assessing Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Simulation Study.

Abualbishr Alshreef, Nicholas Latimer, Paul Tappenden

|Jun 20, 2021
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.

Becky Pennington, Abualbishr Alshreef, Laura Flight

|Jun 16, 2021
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Philip Hykin, A Toby Prevost, Sobha Sivaprasad

|Apr 26, 2021
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.

Becky Pennington, Abualbishr Alshreef, Laura Flight

Pageof 2

Frequent Collaborators

3 joint publications

A Toby Prevost

3 joint publications

Andrew Lotery

3 joint publications

Andrew Metry

3 joint publications

Laura Flight